Precision in Practice: Leveraging Targeted Therapies for HR+/HER2- Breast Cancer

Meeting Objectives:

• • Identify unmet needs and recent trends in using targeted therapies for HR+/HER2- breast cancer.

  • Using real-world patient cases, analyze recent guideline updates and new treatment data from clinical trials to make informed, personalized recommendations for patients with actionable mutations in HR+/HER2- breast cancer.

  • Discuss the integral role of pharmacists in the implementation and management of targeted therapies for HR+/HER2- breast cancer, including biomarker testing, therapy selection, toxicity monitoring and management, and medication adherence.